The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder
The International Journal of Psychiatry in Medicine · 2024
DOI: 10.1177/00912174231210567 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Psychiatry in Medicine, 2024. Verfasst von Mohammad Nadi Sakhvidi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Hauptthemen laut MEDLINE: Celecoxib, Major Depressive Disorder, Drug Therapy, Combination, Escitalopram. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
There is growing evidence that adding non-steroidal anti-inflammatory drugs to some psychopharmacological treatments may help to improve symptoms in patients suffering from major depressive disorder. The present study examined the therapeutic efficacy of adding celecoxib to escitalopram and the safety of doing so.
Method
In this double-blind randomized controlled trial, 60 patients with major depressive disorder were randomly assigned to either treatment with escitalopram plus celecoxib (intervention group) or escitalopram and placebo. All patients were evaluated blind to treatment group with the Hamilton Depression Rating Scale (HDRS) before the intervention as well at 4 and 8 weeks after initiating treatment. Chi-square and paired t-test were used to examine between-group differences at those assessment times.
Results
There was no significant difference in depressive symptoms between intervention and placebo groups at baseline. However, at 4 and 8 weeks after the beginning of treatment, there were significant between-group differences in HDRS scores, favoring the intervention group. No between-group differences were found in treatment-related side effects.
Conclusions
Adding celecoxib to escitalopram may improve symptoms of depression in patients with major depressive disorder without increasing the risk of drug-related side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Psychiatry, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
ORCID-Profile: Zanireh Salami, Malihe Arjmandi
Zitieren
APA
Nadi Sakhvidi, M., Salami, Z., Mosadegh, M., Bidaki, R., Fallahzadeh, H., Salehabadi, R., & Arjmandi, M. (2024). The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/00912174231210567
Vancouver
Nadi Sakhvidi M, Salami Z, Mosadegh M, Bidaki R, Fallahzadeh H, Salehabadi R, et al. The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder. The International Journal of Psychiatry in Medicine. 2024. doi:10.1177/00912174231210567
BibTeX
@article{NadiSakhvidi2024,
author = {Nadi Sakhvidi, Mohammad and Salami, Zanireh and Mosadegh, Maryam and Bidaki, Reza and Fallahzadeh, Hossien and Salehabadi, Razie and Arjmandi, Malihe},
title = {The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder},
journal = {The International Journal of Psychiatry in Medicine},
year = {2024},
doi = {10.1177/00912174231210567}
}
EUVIMED